RAPT Therapeutics (RAPT) Expected to Announce Quarterly Earnings on Thursday

RAPT Therapeutics (NASDAQ:RAPT - Get Free Report) is expected to be releasing its Q1 2025 earnings data before the market opens on Thursday, May 8th. Analysts expect the company to announce earnings of ($0.31) per share for the quarter.

RAPT Therapeutics (NASDAQ:RAPT - Get Free Report) last announced its quarterly earnings results on Thursday, March 6th. The company reported ($1.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.45) by ($0.69). On average, analysts expect RAPT Therapeutics to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

RAPT Therapeutics Stock Down 7.9 %

RAPT Therapeutics stock traded down $0.07 during midday trading on Tuesday, hitting $0.84. 111,050 shares of the stock were exchanged, compared to its average volume of 1,275,928. RAPT Therapeutics has a 52-week low of $0.75 and a 52-week high of $8.44. The business's 50-day moving average price is $1.05 and its 200-day moving average price is $1.28. The stock has a market capitalization of $111.15 million, a price-to-earnings ratio of -0.30 and a beta of -0.04.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a "buy" rating and set a $10.00 price target on shares of RAPT Therapeutics in a research report on Monday, March 10th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat, RAPT Therapeutics has an average rating of "Hold" and an average target price of $4.00.

RAPT Therapeutics Company Profile

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.